
Scribe Therapeutics raises $129M in IPO priced at high end, valuing company at $273M
Scribe Therapeutics, a biotech focused on cardiovascular disease, priced its IPO at the high end, raising $129 million with a market valuation of $273 million. This IPO was one of five public offerings last week, including four SPACs. Looking ahead, ...



